Ogen
Executive Summary
Upjohn acquires rights to Abbott's Ogen (estropipate) tablets and vaginal cream. While Ogen has competed with Ortho's Ortho-Est since 1991, generic competition has intensified only recently with the September ANDA approval of Watson's estropipate and with Duramed's December introduction of a generic version supplied by Ortho